EpiCast Report: Immune Thrombocytopenia (ITP) - Epidemiology Forecast to 2025

  • ID: 4027823
  • Drug Pipelines
  • 67 pages
  • GlobalData
1 of 3
Immune thrombocytopenia (ITP) is an autoimmune syndrome involving the antibody- and cell-mediated destruction of platelets and the suppression of platelet production; this increases an affected individual’s susceptibility to bleeding (Cuker and Cines, 2010). More specifically, the destruction and suppression of platelets are due to B cell (and sometimes CD8+ T cell) autoimmune reactions directed against circulating platelets and megakaryocytes. About 80% of all ITP cases are considered to be idiopathic, also known as primary ITP. The remaining 20% of ITP cases occur as a component of another clinically evident disorder, such as hepatitis C or systemic lupus erythematosus, or drug exposure; these cases are categorized as secondary ITP (Cuker and Cines, 2010).

The main risk factors for ITP include age, sex, some infections, certain medications, and genetics (Bennett et al., 2011; NIH, 2012). Overall, older versus younger age groups and women versus men are more likely to have ITP (Bennett et al., 2011; Feudjo-Tepie et al., 2008; Schoonen et al., 2009).

In the 7MM, the diagnosed prevalent cases of primary and secondary ITP will increase from 359,208 cases in 2015 to 384,780 cases in 2025 at an annual growth rate (AGR) of 0.71%. The 5EU will have the highest number of diagnosed prevalent cases throughout the forecast period with 179,350 cases in 2015 and 191,229 cases in 2025, while Japan will have the lowest number of diagnosed prevalent cases with 24,468 in 2015 and 24,479 in 2025.

In the 7MM, the diagnosed incident cases of primary and secondary ITP will increase from 33,136 cases in 2015 to 35,364 cases in 2025, at an AGR of 0.67%. Similar to the prevalent cases, the 5EU had the highest incident cases of primary and secondary ITP with 15,674 cases in 2015, and 16,530 cases in 2025, while Japan had the least with 2,788 cases in 2015, and 2,836 in 2025.

The report “EpiCast Report: Immune Thrombocytopenia (ITP) - Epidemiology Forecast to 2025” provides an overview of the risk factors, comorbidities, and global and historical trends for ITP in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent and diagnosed incident cases of ITP segmented by type (primary and secondary), sex, and age (in twenty-year age groups beginning at 0 years and ending at 80 years and older).
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1.1 List of Tables

1.2 List of Figures

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global Trends

2.3.1 US

2.3.2 5EU

2.3.3 Japan

2.4 Forecast Methodology

2.4.1 Sources Used Tables

2.4.2 Forecast Assumptions and Methods

2.4.3 Sources Not Used

2.5 Epidemiological Forecast for ITP (2015-2025)

2.5.1 Diagnosed Prevalent Cases of ITP

2.5.2 Age-Specific Diagnosed Prevalent Cases of ITP

2.5.3 Sex-Specific Diagnosed Prevalent Cases of ITP

2.5.4 Age-Standardized Diagnosed Prevalence of ITP

2.5.5 Diagnosed Incident Cases of ITP

2.5.6 Age-Specific Diagnosed Incident Cases of ITP

2.5.7 Sex-Specific Diagnosed Incident Cases of ITP

2.5.8 Age-Standardized Diagnosed Incidence of ITP

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 Limitations of the Analysis

2.6.3 Strengths of the Analysis

3 Appendix

3.1 Bibliography

3.2 Physicians and Specialists Included in this Study

3.3 About the Authors

3.3.1 Epidemiologists

3.3.2 Reviewers

3.3.3 Global Director of Therapy Analysis and Epidemiology

3.3.4 Global Head of Healthcare

3.4 About the Author

3.5 About EpiCast

3.6 Disclaimer

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for ITP

Table 2: 7MM, Sources for Diagnosed Prevalence of Primary ITP

Table 3: 7MM, Sources for Diagnosed Prevalence of Secondary ITP

Table 4: 7MM, Sources for Diagnosed Incidence of Primary ITP

Table 5: 7MM, Sources for Diagnosed Incidence of Secondary ITP

Table 6: 7MM, Sources Not Used in the Epidemiological Analysis of ITP

Table 7: 7MM, Diagnosed Prevalent Cases of Primary ITP, All Ages, Men and Women, Select Years, 2015-2025

Table 8: 6MM, Diagnosed Prevalent Cases of Secondary ITP, All Ages, Men and Women, Select Years, 2015-2025

Table 9: 7MM, Age-Specific Diagnosed Prevalent Cases of Primary ITP, Men and Women, N (Row %), 2015

Table 10: 6MM, Age-Specific Diagnosed Prevalent Cases of Secondary ITP, Men and Women, N (Row %), 2015

Table 11: 7MM, Sex-Specific Diagnosed Prevalent Cases of Primary ITP, All Ages, N (Row %), 2015

Table 12: 6MM, Sex-Specific Diagnosed Prevalent Cases of Secondary ITP, All Ages, N, 2015

Table 13: 7MM, Diagnosed Incident Cases of Primary ITP, All Ages, Men and Women, Select Years, 2015-2025

Table 14: 6MM, Diagnosed Incident Cases of Secondary ITP, All Ages, Men and Women, Select Years, 2015-2025

Table 15: 7MM, Age-Specific Diagnosed Incident Cases of Primary ITP, Men and Women, N (Row %), 2015

Table 16: 6MM, Age-Specific Diagnosed Incident Cases of Secondary ITP, Men and Women, N (Row %), 2015

Table 17: 7MM, Sex-Specific Diagnosed Incident Cases of Primary ITP, All Ages, N (Row %), 2015

Table 18: 6MM, Sex-Specific Diagnosed Incident Cases of Secondary ITP, All Ages, N (Row %), 2015

1.2 List of Figures

Figure 1: Diagnosed Prevalence Rate for ITP in the 7MM for All Ages, Men and Women, Cases per 100,000 Population, 2015

Figure 2: Diagnosed Incidence Rate for ITP in the 7MM for All Ages, Men and Women, Cases per 100,000 Population, 2015

Figure 3: Case Flow Map

Figure 4: 7MM, Diagnosed Prevalent Cases of Primary ITP Cases, All Ages, Men and Women, N, Select Years, 2015-2025

Figure 5: 6MM, Diagnosed Prevalent Cases of Secondary ITP Cases, All Ages, Men and Women, N,

Figure 6: 7MM, Age-Specific Diagnosed Prevalent Cases of Primary ITP, Men and Women, N, 2015

Figure 7: 6MM, Age-Specific Diagnosed Prevalent Cases of Secondary ITP, Men and Women, N, 2015

Figure 8: 7MM, Sex-Specific Diagnosed Prevalent Cases of Primary ITP, All Ages, N, 2015

Figure 9: 6MM, Sex-Specific Diagnosed Prevalent Cases of Secondary ITP, All Ages, N, 2015

Figure 10: 7MM, Age-Standardized Diagnosed Prevalence of Primary ITP, All Ages, Cases per 100,000 population, 2015

Figure 11: 6MM, Age-Standardized Diagnosed Prevalence of Secondary ITP, All Ages, Cases per 100,000 population, 2015

Figure 12: 7MM, Diagnosed Incident Cases of Primary ITP, All Ages, Men and Women, N, Select Years, 2015-2025

Figure 13: 6MM, Diagnosed Incident Cases of Secondary ITP, All Ages, Men and Women, N, Select Years, 2015-2025

Figure 14: 7MM, Age-Specific Diagnosed Incident Cases of Primary ITP, Men and Women, N, 2015

Figure 15: 6MM, Age-Specific Diagnosed Incident Cases of Secondary ITP, Men and Women, N, 2015

Figure 16: 7MM, Sex-Specific Diagnosed Incident Cases of Primary ITP, All Ages, N, 2015

Figure 17: shows the sex-specific diagnosed incident cases of secondary ITP in the 6MM.

Figure 18: 7MM, Age-Standardized Diagnosed Incidence of Primary ITP, All Ages, Cases per 100,000 Population, 2015

Figure 19: 6MM, Age-Standardized Diagnosed Incidence of Secondary ITP, All Ages, Cases per 100,000 Population, 2015
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll